Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 45: 388-393, 1999;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wei, T. Q.
Right arrow Articles by Thompson, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wei, T. Q.
Right arrow Articles by Thompson, J. C.
Related Collections
Right arrow Drug Monitoring and Toxicology
(Clinical Chemistry. 1999;45:388-393.)
© 1999 American Association for Clinical Chemistry, Inc.

Articles

Automated Homogeneous Immunoassay for Gentamicin on the Dimension Clinical Chemistry System

Tie Q. Weia, Victor P. Chu, Alan R. Craig, James E. Duffy, David M. Obzansky, Daniel Kilgore, Ignazio S. Masulli, Connie M. Sanders and John C. Thompson

a Author for correspondence. Fax 302-631-7487; e-mail weitq{at}dadebehring.com

Background: Monitoring of the concentration of gentamicin in serum and plasma during therapy is widely recommended and practiced in hospitals. Our aim was to develop a homogeneous immunoassay based on particle-enhanced turbidimetric inhibition immunoassay technology to quantify gentamicin on the Dimension® clinical chemistry system.

Methods: Assay performance was assessed on each of the Dimension models in a 15-instrument interlaboratory comparison study. A split-sample comparison (n = 1171) was also performed between the gentamicin methods on the Dimension system and the Abbott®TDx® analyzer, using multiple reagent and calibrator lots on multiple instruments.

Results: The Dimension method was linear to 25.1 µmol/L (12.0 µg/mL) with a detection limit of 0.63 µmol/L (0.3 µg/mL). Calibration was stable for 30 days. The within-run imprecision (CV) was <1.3%, and total imprecision ranged from 1.8% to 3.2% between 4.2 µmol/L (2.0 µg/mL) and 16.7 µmol/L (8.0 µg/mL) gentamicin. Linear regression analysis of the results on the Dimension method (DM) vs the Abbott TDx yielded the following equation: DM = 0.98TDx - 0.42; r = 0.987. Minimal interference was observed from structurally related compounds such as sagamicin, netilmicin, and sisomicin.

Conclusion: The monoclonal antibody used in this method has similar reactivities toward the individual gentamicin subspecies C1, C1a, and C2, thus providing analytical recovery not significantly dependent on relative subspecies concentrations. © 1999 American Association for Clinical Chemistry




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
N. Isoherranen and S. Soback
Determination of Gentamicins C1, C1a, and C2 in Plasma and Urine by HPLC
Clin. Chem., June 1, 2000; 46(6): 837 - 842.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1999 by the American Association for Clinical Chemistry.